AG真人官方

Schedule 13G/A (Amendment 2) filed 31 Jul 2025 shows that four Canadian investment advisers linked to Scotiabank 鈥� 1832 Asset Management L.P., MD Financial Management Inc., Scotia McLeod (Scotia Capital Inc.) and Jarislowsky, Fraser Ltd 鈥� collectively owned 22,630,889 Brookfield Infrastructure Partners (BIP) LP units on 30 Jun 2025, equal to 4.90 % of the outstanding class.

Voting/dispositive authority is largely unilateral: sole power over 22,603,439 units and shared power over only 27,450 units. Individual stakes are: 1832 AM 15.45 m units (3.35 %), Scotia McLeod 7.15 m (1.55 %), MD Financial 25 k (0.01 %) and Jarislowsky Fraser 3.2 k (<0.01 %).

The group now certifies ownership of 5 % or less, indicating a position below the threshold that would otherwise trigger Schedule 13D obligations. The securities are held in the ordinary course of business with no intent to influence control.

Insider activity: On 07/29/2025, Select Medical Holdings (SEM) Executive Chairman & Director Robert A. Ortenzio received 250,000 restricted shares at $0. The grant vests in three equal annual installments over the next three years.

Post-transaction, Ortenzio owns 7,081,788 shares directly and 2,120,245 shares indirectly through family trusts, for total exposure of roughly 9.2 million shares. No shares were sold and no options or other derivatives were involved.

The award modestly dilutes shareholders (鈮�0.18% of SEM鈥檚 136 m shares outstanding) but reinforces insider alignment as the founder increases his stake without cash outflow.

On 30 Jun 2025, four Canadian investment firms jointly filed a Schedule 13G disclosing a new >5 % passive stake in Gildan Activewear Inc. (NYSE: GIL).

• Total beneficial ownership: 7,678,872 common shares, representing 5.10 % of shares outstanding.
• Largest holder: Jarislowsky, Fraser Ltd. with 7,412,206 shares (4.92 %).
• Other filers: 1832 Asset Management L.P. (61,336); MD Financial Management Inc. (105,450); Scotia McLeod / Scotia Capital (99,880).
• Sole voting & dispositive power: 7,678,272 shares; shared power: 600 shares.
• Filed under Rule 13d-1(b) as institutional investors (FI/IA); certification states the stake is held in the ordinary course with no intent to influence control.

The disclosure signals incremental institutional interest but does not indicate activist activity or strategic intent. Investors may view the ownership as a modest vote of confidence from well-known Canadian asset managers.

The filing is a Form 144/A notice indicating that insider Richard Wurster intends to sell up to 20,500 common shares of The Charles Schwab Corporation (SCHW) through broker Charles Schwab Corp. on or after 29 Jul 2025. At the stated aggregate market value of $2.03 million, the proposed sale equals roughly 0.001 % of the 1.82 billion shares outstanding, making it immaterial to the float.

The shares were acquired as RSUs between 25 Oct 2022 and 1 Mar 2024. The filer previously sold 15,345 shares on 9 May 2025 for $1.29 million. No undisclosed adverse information is asserted in the certification statement.

Form 144 filings signal possible insider sales but are not binding; actual transactions may depend on Rule 10b5-1 plans and market conditions. Given the limited size, the filing is unlikely to affect SCHW鈥檚 valuation, though continued selling by senior insiders can influence sentiment.

Insider Walter Bettinger has filed Form 144 for The Charles Schwab Corp. (SCHW), signaling an intent to sell up to 173,876 common shares through Charles Schwab & Co. on or about 29 Jul 2025. At the stated reference price, the proposed sale is valued at roughly $17.2 million, equal to 鈮�0.01 % of the company鈥檚 1.82 billion shares outstanding.

The filing also notes that Bettinger sold 191,523 shares on 19 May 2025, generating $17.0 million in gross proceeds. The shares being offered were obtained via vesting of performance-based RSUs on 2 Mar 2023. By signing, the filer attests to having no undisclosed material adverse information about the company.

Charles Schwab Corp. (SCHW) 鈥� Form 144 filing: The notice discloses a planned sale of 24,096 common shares on 29 Jul 2025 through The Charles Schwab Corp. brokerage, with an aggregate market value of $2.36 million. The shares were acquired the same day via stock-option exercise. Schwab reports 1.817 billion shares outstanding, so the proposed sale represents roughly 0.001 % of total float.

The filer鈥攊dentified in earlier sales data as Nigel Murtagh鈥攑reviously sold 70,872 shares during the last three months, generating $6.21 million in gross proceeds across three transactions (8 May, 28 May and 18 Jun 2025). No adverse undisclosed information is claimed by the seller, as required by Rule 144 representations.

The filing signals continued, but modest, insider-level divestment. Given the tiny percentage of total shares and the option-exercise origin, the transaction appears routine and is unlikely to affect SCHW鈥檚 capital structure or market liquidity.

The Charles Schwab Corporation (SCHW) filed a Form 144 indicating that insider Richard Wurster plans to sell up to 20,500 common shares (鈮� 0.002 % of the 1.82 billion shares outstanding). Based on the filing鈥檚 reference price, the transaction is valued at 鈮� $2.03 million. The shares were acquired on 03 Mar 2025 through the vesting of performance-based RSUs.

The filing also discloses that Wurster has already sold 15,345 shares for $1.29 million on 09 May 2025. If the proposed sale proceeds, his cumulative disposals over three months would reach 35,845 shares worth roughly $3.32 million.

While insider sales can signal reduced personal exposure, the volume is immaterial relative to Schwab鈥檚 float and does not affect corporate fundamentals. The transaction is routed through The Charles Schwab Corporation鈥檚 brokerage and will occur on the NYSE around 29 Jul 2025, consistent with Rule 144 requirements. No earnings, guidance, or operational updates are included in this notice.

Charles Schwab Corp. (SCHW) 鈥� Form 4 insider transaction: Director Carolyn Schwab-Pomerantz reported two Rule 10b5-1 programmed sales executed on 07/03/2025.

• Shares sold: 14,400 shares held in trust at a weighted-average price of $91.5906 and 9,600 shares held by spouse-as-trustee at $91.5885; total 24,000 shares (~$2.2 million).
• Remaining beneficial ownership: 1,491,598.6599 shares indirectly via trust, 469,714 shares indirectly via spouse, 9,624 shares held directly, and 2,798 shares via LLC.
• Trading plan: Sales executed under a 10b5-1 plan adopted 08/14/2024, indicating pre-arranged, automatic transactions.

No derivative securities were involved and there is no indication of additional transactions. The sale represents a small fraction of the insider鈥檚 total holdings and appears to be routine diversification rather than a signal of fundamental change.